NLS Pharmaceutics AG: NLS Pharmaceutics Announces Over Enrollment in its Phase 2a Clinical Trial Evaluating Quilience for the Treatment of Narcolepsy

60-patient enrollment target met plus 12% over-enrollment; top-line Phase 2a results expected to be presented during the European Sleep Research Society Congress in September 2022Nearly 90% of patients

Related Keywords

United States ,Athens ,Attikír ,Greece ,Zurich ,Züsz ,Switzerland ,Swiss ,Alex Zwyer ,Cindy Rizzo ,Pascal Nigen ,Exchange Commission ,Alpha Bronze ,World Sleep Congress ,Nasdaq ,Pharmaceutics Ltd ,European Sleep Research Society Congress ,Chief Executive Officer ,Mazindol Controlled Release ,Orphan Drug Designations ,Pharmaceutics ,Nnounces ,Dover ,Enrollment ,Hase ,Linical ,Trial ,Valuating ,Uilience ,Treatment ,Narcolepsy ,